KHK 2866

Drug Profile

KHK 2866

Alternative Names: KHK2866

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko Kirin
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Heparin binding EGF like growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ovarian cancer; Solid tumours

Most Recent Events

  • 17 Apr 2013 Discontinued - Phase-I for Ovarian cancer in USA (IV)
  • 05 Mar 2013 Kyowa Hakko Kirin Pharma terminates its phase I trial in Solid tumours including Ovarian cancer in USA (NCT01279291)
  • 11 Jan 2011 Phase-I clinical trials in Ovarian cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top